In the past 20 years, several pathogen inactivation technologies have been developed to be applied to blood components. This review is intended to summarize the data currently available about the technologies and the clinical use of products inactivated by those techniques.
INTRODUCTION
From the point of view of infectious risks, current blood components are the safest that we have ever had, but from a public perspective, can they ever be safe enough? Despite measures implemented to detect them, bacteria continue to be a measurable risk for the recipient of platelet transfusions, and in some highly endemic countries the risk of hepatitis, particularly hepatitis B, is not negligible even after implementing the most sensitive screening techniques. An always present threat are those pathogens we do not screen for, that is, emergent or re-emergent pathogens [1 && ]. In the early 1990s, the first pathogen inactivation techniques were developed for plasma. Since then other technologies have been developed not only for plasma but also for platelets. This review summarizes available data, mainly related to the inactivation capacity and the clinical experience, which support the idea that pathogen inactivation for blood components is, finally coming of age.
TECHNOLOGIES FOR PLASMA
Plasma is a liquid suspension of several proteins, lipids, and salts, and was the first labile blood component for which pathogen activation technologies were developed.
Methylene blue method
The first procedure described for inactivating pathogens in plasma was the use of methylene blue. In 1991, Lambrecht et al. [2] described a method to inactivate virus in plasma using methylene blue dye and visible light (MB-L). MB-L treatment (not including the freeze-thawing procedure) affects several coagulation factors, most noticeably fibrinogen and factor (F)VIII, with a loss of approximately 30% [3, 4] . The activities of the other clotting factors are less affected, and some of these proteins, such as the physiologic coagulation inhibitors and complement factors, are not affected at all [5] .
Clinical studies
Most studies of MB-L-treated plasma in patients have been small and/or have used laboratory rather than clinical endpoints and had usually been reported as an abstract to a scientific meeting. Despite the usage of more than 1 million units of MB-L plasma in Europe, there are few reports of large, randomized trials of MB-L-treated plasma using relevant endpoints such as blood loss or exposure to other blood components [5] . One study involving 71 patients compared MB-L plasma with solvent-detergent-treated fresh frozen plasma (FFP) in cardiac surgery and showed better replacement of protein S and alpha2-antiplasmin with MB-Ltreated plasma but no difference in blood loss [6] . Recently, a randomized prospective trial compared the clinical efficacy of MB-L plasma, solvent-detergent plasma, and quarantine (Q) plasma in patients undergoing liver transplantation. The plasma volume administered during the transplantation served as primary endpoint. The authors observed that a greater volume of MB-L plasma needed to be used compared with Q plasma or solvent/detergent plasma for similar clinical efficacy. However, differences in conditioning volume per plasma unit as well as imbalance in bleeding risk factors precluded definitive conclusions as to differential efficacy between MB-L plasma, solvent-detergent plasma, and Q-plasma in the setting of liver transplantation [7 & ].
In 2008, a multicenter prospective cohort Spanish study compared MB-L-plasma to quarantine plasma in the treatment of thrombotic thrombocytopenic purpura (TTP). Patients treated with MB-L plasma required more plasma exchanges (median: 11 vs. 5, P ¼ 0.002) and a larger volume of plasma (median: 485 vs. 216 ml/kg, P ¼ 0.007) to achieve a remission. Moreover, more relapses were seen in patients while on plasma exchange therapy (29 of 63 vs. 8 of 39, P ¼ 0.02) than those who received quarantined plasma [8, 9] . However, as all the studies performed have been observational, a prospective, randomized, controlled trial with sufficient power would be required to establish the role for MB-L plasma in the treatment of TTP [10] .
As a result of an apparent increase in the frequency of allergic reactions associated with the transfusion of MB-L-treated plasma [11] [12] [13] , the French Agency for the Safety of Health Products (Agence Française de Sécurité Sanitaire des Produits de Santé, AFSSAP) announced in October 2011 that the authorization to produce MB-L plasma would be cancelled in France and its production stopped in a progressive way to guarantee the availability of inactivated plasma for transfusion. MB-L plasma was completely removed from transfusion as of 1 March 2012 [14] . Interestingly, an increase in allergic reactions in patients receiving MB-L plasma was not found when hemovigilance data from a French region over a 10-year period were analyzed [15 && ], nor when data from a United Kingdom hemovigilance scheme were specifically analyzed [16 && ].
Solvent-detergent method
In 1992, a method originally developed for coagulation factor concentrates was adapted for human plasma by two different groups in Europe and the United States [17, 18] . This method is based on the addition of an organic solvent, which removes lipids from viral membranes, and an ionic detergent, which disrupts lipid bilayers. Following this common step, significant differences exist between the two methods applied in both the United States and Europe [19] . Such changes in the preparation methodology have a noticeable effect in the coagulation factor profile of the final product. Thus, in comparison to the European product, protein S activity and plasminogen activation inhibitor type 1 are almost absent, and the citrate concentration lower, in the US product [20] .
Clinical studies
At least 11 studies have been conducted to examine the efficacy and tolerance of solvent-detergenttreated plasma. Four of these trials were designed as prospective randomized studies to compare solvent-detergent with standard FFP or MB-L-treated
KEY POINTS
Several technologies are currently available (and licensed in the European Union) for inactivating pathogens transmitted by transfusion in plasma and platelet components.
The mechanism of action, and the spectrum and level of inactivation of pathogens vary among the different technologies. In addition, the number of studies with clinically relevant endpoints and the number of patients included in the studies vary widely.
Both preclinical and clinical studies and experience in postapproval use for some of the technologies suggest that the treated blood components meet required safety and efficacy criteria.
The use of pathogen inactivation for blood components is not widespread. Differences in epidemiology between countries, infectious risk perception, concerns about potential adverse effects associated with its use, and economic considerations might explain the differences observed in its implementation.
plasma. Although the studies involved relatively small numbers of patients and therefore lack the statistical power to detect minor differences, reduced coagulation factor and inhibitor levels caused by solvent-detergent treatment were not observed to result in impairment of clinical efficacy [21] . However, concerns were raised about the potential association of venous thromboembolism and plasma exchange treatment performed with solventdetergent in patients suffering from TTP. A retrospective study found eight thromboembolic episodes in patients receiving Octaplas (the treated solventdetergent plasma marketed in Europe by Octapharma) as a replacement solution in plasma exchanges for treating TTP [22] . However, the same group reported 4 years later a retrospective study in which a new cohort of patients treated with Octaplas were compared to patients receiving cryoprecipitate poor plasma. They found no differences between the two groups either in terms of number of plasma exchanges to remission or thromboembolic episodes [23] . In 2002, Vitex, the American company producing solvent-detergent plasma, ceased the production because of reports of venous thromboembolism in TTP patients and a cluster of six deaths in liver transplantation patients [24 && ].
Amotosalen/light-treated plasma
The amotosalen and light method is based on the addition of a novel psoralen, amotosalen, and the illumination with long-wavelength ultraviolet light (UVA). The combination of 150 mmol/l amotosalen and 3 J/cm 2 of UVA light (A-L, Intercept Blood System; Cerus Europe, BV, Amersfoort, the Netherlands) was shown to inactivate high levels of enveloped and nonenveloped viruses, bacteria, and protozoa in plasma and platelet concentrates resuspended in platelet additive solution (PAS) [25 && ]. After treating plasma with A-L, a decrease in several coagulation factors is observed, including fibrinogen and FVIII (up to 26% mean reduction), whereas other clotting factors remained undiminished in activity [(FII, FV, FVII, FIX, FX, FXI, and FXIII (81-97%)]. von Willebrand factor (vWF), coagulation physiologic inhibitors (antithrombin and proteins S and C), and the metalloprotease ADAMTS-13 remained also essentially unmodified [26] [27] [28] .
Clinical studies
There are three studies in which the efficacy and safety of plasma treated with A-L in different clinical situations is studied. One study examined the kinetics of specific coagulation factors, hemostatic efficacy, and the safety of A-L-treated plasma in 34 patients with congenital coagulation factor deficiencies, exhibiting A-L-treated plasma kinetics and therapeutic efficacy consistent with that seen with untreated plasma [29] . No differences were observed in use of blood components, clinical hemostasis, or safety between the two groups in a prospective, controlled study in patients with acquired coagulopathy, comparing A-L-treated plasma with standard FFP. A third randomized controlled, double-blinded trial conducted with A-L plasma or standard plasma for therapeutic plasma exchange in 35 patients with TTP did not find significant differences regarding treatment response or side-effects [30] .
Riboflavin/light-treated plasma
In 2000, Goodrich [31] reported the potential use of vitamin B 2 (riboflavin) and light (RB-L) for inactivating pathogens in platelet concentrates and plasma (Mirasol PRT System; Terumo BCT, Lakewood, Colorado, USA). Pathogen inactivation with RB-L has been tested with a wide variety of enveloped and nonenveloped viruses (no data for hepatitis A virus are available), Gram-negative and Gram-positive bacteria as well as parasites [32] [33] [34] [35] .
Treatment of plasma with RB-L is associated with a loss of coagulation factor activity with a mean loss of 32% for FXI, and over 21% for FVIII, fibrinogen, FV, FVII, FIX, and FX. vWF antigen, vWF:ristocetin cofactor, and ADAMTS-13 recoveries were 87%, 85% and 73%, respectively, while that of protein C was 83%. A loss of high-molecular-weight vWF multimers was observed in most units. Recoveries for protein S, antithrombin, and plasmin inhibitor were greater than 90%. The authors concluded that for most units and for most of the tested factors this is unlikely to have clinical impact, but trials are required to allow this conclusion to be made [36] . So far no clinical studies have been reported for the use of RB-L-treated plasma.
TECHNOLOGIES FOR PLATELET CONCENTRATES
Platelets are activated by a wide variety of stimuli to facilitate hemostasis, but this sensitivity to activation provides considerable challenges during platelet manipulation. Activation during preparation and storage of platelet concentrates can have a deleterious effect on the recovery and survival of treated platelets when transfused. To date, two pathogen inactivation technologies have been developed and marketed in the European Union: one based on A-L and the other on RB-L. A third one, based on the illumination with ultraviolet C, is currently under development [37 && ].
Amotosalen/light-treated platelet concentrates
The Intercept system for platelet concentrates is similar to that described previously in the plasma section. Active hemovigilance data from Europe with more than 12 000 platelet transfusions suggest that A-L-treated platelet concentrates show a safety profile similar to that previously reported for conventional platelets [38, 39, 40 && ]. Several studies have looked at the effect of the A-L treatment on in-vitro functions of the platelet during preparation and storage, showing that the characteristics of the A-L-treated platelet were acceptably preserved [41, 42] . Studies of the recovery and survival of treated platelets in healthy individuals showed a statistically significant in-vivo lower recovery (42.5 vs. 50.3%) and survival (4.8 vs. 6.0 days) [43] .
Clinical studies
Several clinical studies that have included more than 1000 patients have looked at the effect of A-L treatment on platelet concentrates. The first clinical study published was the euroSPRITE study, a multicenter, controlled, randomized, doubleblinded trial in thrombocytopenic patients requiring repeated platelet transfusions conducted in Europe. One hundred three patients were randomized to receive A-L-treated platelet concentrates (311 transfusions) or control platelets (256 transfusions). The mean 1-h posttransfusion count increment for up to the first eight transfusions was statistically significantly lower in the patients receiving the A-L-treated platelet concentrates compared with control platelet concentrates (27.5 vs. 35.8, P ¼ 0.03), but not the 1-h corrected count increment (CCI; 13 100 vs. 14 900, P ¼ 0.11). Clinical hemostasis, hemorrhagic adverse events, and overall adverse events were not different between treatment groups [44] .
The SPRINT trial looked at the proportion of patients with WHO grade 2 or higher bleeding during the period of platelet support. A total of 645 patients (318 A-L platelet concentrates and 327 control platelet concentrates) were evaluated. The incidence of grade 2 or higher bleeding (58.5% A-L platelet concentrates vs. 57.5% control platelet concentrates), and the secondary endpoint, the incidence of grade 3 or 4 bleeding (4.1% A-L vs. 6.1% control), were equivalent between the two groups (P ¼ 0.001 by noninferiority). Transfusion reactions were fewer following A-L-treated platelets (3.0% A-L platelet concentrates vs. 4.4% control platelet concentrates, P ¼ 0.02) [45] .
A multicenter, randomized, controlled, double blinded clinical trial comparing A-L-treated platelet concentrates with control platelet concentrates stored for 6 or 7 days (TESSI study) has been reported. The primary endpoint (the 1-h CCI evaluated with a noninferiority margin ratio of A-Ltreated/control >0.70) showed no statistically significant difference (0.87, 95% confidence interval: 0.73-1.03). The number of red blood cell (RBC) units transfused 24 h after study platelet concentrates and maximal posttransfusion hemostatic scores were also not significantly different between groups. Acute transfusion reactions, hemorrhagic adverse event, overall adverse event, and serious adverse event were not significantly different between the A-L and treated groups [46] .
A Dutch-Belgian HOVON cooperative group has reported the results of a study in which they looked at the clinical effectiveness of buffy-coatderived leucoreduced platelet concentrates stored up to 7 days in plasma, in PAS with or without A-L treatment [47] . The authors reported that the primary endpoint of the study, 1-h CCI, was reduced 31% for A-L-treated group in comparison to platelet concentrates in plasma (P <0.0001). In addition, 32% of patients had bleeding events (most of them mild) in the A-L arm, as compared with 19% (P ¼ 0.045) in the plasma arm. It is worthy of notice that the patients in the A-L arm had a mean pretransfusion platelet count significantly lower in comparison with patients receiving platelet products in plasma (16 AE 11 vs. 18 AE 13, P ¼ 0.04) and that the mean platelet content per transfused product was also significantly lower (3.9 AE 1.0 Â 10 11 vs. 3.4 AE 0.8 Â 10 11 , P <0.0001). The authors admitted that the number of off-protocol transfusions in the A-L arm (34%) was an important limitation of the study and that the open label aspect of the study might have biased the evaluation of bleeding [47] . Actually in the PLADO study, in which the bleeding was evaluated by specifically trained blinded personnel, grade 2 bleeding (gross, symptomatic bleeding, and oropharyngeal bleeding or epistaxis for more than 30 min during a 24-h period) was found in 60% [48] , as compared with HOVON, in which the incidence was 6% in the plasma arm.
Meta-analysis is a useful statistical tool that allows the combination of different studies, in the hope of identifying among different study results patterns, source of disagreements, or other relationships. So far, there are three meta-analyses published dealing with the results of clinical studies related to pathogen inactivation technologies [ Interestingly, one center has reported a decrease in the incidence of human leukocyte antigens (3.7 vs. 1.1%) and human platelet antigens (HPA) seroconversion (2.6 vs. 0.4%) in hematologic patients receiving platelet support after implementing A-L-treated platelet components, which was statistically significant in the case of HPA seroconversion (P ¼ 0.03) [52] .
Riboflavin/light-treated platelet concentrates
The Mirasol PRT System for platelet concentrates developed by Terumo BCT is identical to that described for plasma. The RB-L process allows treatment of platelets collected in either plasma or PAS, with PAS IIIM being the recommended PAS for longer storage [53, 54 && ]. In-vitro studies have characterized the impact of the pathogen inactivation process in platelet concentrates prepared by both the buffy coat method and by apheresis. From them, it can be concluded that although the RB-L treatment increases the storage lesions of platelets, the levels of such increase seem tolerable for clinical use [55] . Adhesive and aggregative capacities of treated platelets under flow conditions were also similar to those of the nontreated platelets, although platelet activation markers were, after 5 days of storage, significantly higher for RB-L-treated platelet concentrates than for control products [56] . Studies with radiolabeled platelets in healthy individuals have shown that the treatment with RB-L of apheresis platelets is associated with a significant decrease in recovery (50 vs. 66.5%) and survival (104 vs. 142 h), with respect to nontreated platelets [57] .
Clinical studies A randomized, controlled clinical trial compared platelet concentrates treated with RB-L in plasma and nontreated platelet concentrates. The primary endpoint was 1-h CCI calculated from the first eight on protocol platelet transfusions. One hundred eighteen patients were randomized (60 RB-L platelet concentrates and 58 control platelet concentrates). A total of 541 platelet transfusions were given (303 RB-L and 238 control). The least square mean CCI was significantly different (P <0.0001) for RB-Ltreated platelet concentrates (11 725) compared with control platelet concentrates (16 939) . The authors concluded that although the study failed to show noninferiority of RB-L-treated platelet concentrates, platelet and RBC utilization in the two groups were not significantly different. Further studies are clearly required to determine whether the lower CCIs translate into an increased risk of bleeding [58] .
CONCLUSION
Several pathogen inactivation technologies applicable to labile blood components such as plasma and platelets are currently available and marketed, at least in the European Union. The increased experience available from preclinical and clinical studies, as well as with routine use, suggests that they meet the required safety and efficacy criteria for the implementation. However, use remains sporadic, probably reflecting both varied perceptions of residual risk and capacity to afford the additional economic requirements of implementing additional safety technologies.
